ArticleAnnals of medicine2025
Forrest-type IIb increases the risk of rebleeding after endoscopic treatment in patients with Dieulafoy's lesion of the upper gastrointestinal tract.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Smoking and Early Readmission After NVUGIB: Clinical and Mechanistic Considerations.Digestive diseases and sciences · 2026Article
- Experience of the endoscopist mediates the association between weekend effect with rebleeding after endoscopic treatment for Dieulafoy's lesion.Surgical endoscopy · 2026Article
- Development, validation, and web deployment of a rebleeding risk prediction model for acute non-variceal upper gastrointestinal bleeding in a Chinese population.Frontiers in medicine · 2025Article
- Analysis of factors associated with 1-year rebleeding in patients with acute upper gastrointestinal bleeding and a Glasgow- Blatchford Score ≥ 6 based on serological indicators.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDieulafoy's lesion (DL) is a rare cause of nonvariceal upper gastrointestinal bleeding (NVUGIB) and represents a significant clinical challenge. This research aimed to identify the potential risk factors contributing to DL rebleeding after endoscopic hemostasis, including patient characteristics and laboratory and endoscopic findings such as the Forrest classification.
methodsThis retrospective study encompassed patients diagnosed with upper gastrointestinal DL who received standard endoscopic hemostasis between April 2007 and June 2024. Patients included in this study were categorized into the rebleeding and non-rebleeding groups. Univariate and multivariate logistic regression analyses were used to identify risk factors for DL rebleeding.
resultsOf the 272 patients included in this study, rebleeding occurred in 46 (16.9%). Multivariate logistic regression demonstrated that Forrest-type IIb lesions (odds ratio [OR] 3.86, 95% confidence intervals [CI] 1.16-12.83,
conclusionForrest-type IIb lesions and less experienced endoscopists were independent risk factors for DL rebleeding in the upper gastrointestinal tract after endoscopic hemostasis. More attention should be given to DL presenting as Forrest-type IIb, as rebleeding is often closely associated with a worse clinical prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.